Disappointed InDex CONCLUDEs Development Of Ulcerative Colitis Drug

 
• By Kevin Grogan

The Swedish biotech's hopes of advancing cobitolimod lie in tatters after a Phase III study of the TLR9 agonist proved futile.

Jenny Sundqvist
Jenny Sundqvist • Source: InDex

More from Alimentary/Metabolic

More from Therapy Areas